replacement), indicates an enrichment of stem cell markers upon castration; CD44, NKX3.1 and ALDH1 isoforms. Microarray analysis has confirmed upregulation of CD44 and ALDH1A1 at castrated state, versus downregulation upon androgen replacement at early time points (24 hours). We isolated CD44þ/-ALDHhigh/low subpopulations by flow cytometry for transcriptome analysis. Castration in the BM-18 model induces an increase in the subpopulations of CD44þ/ALDHlow (from 0.44% to 2.3%) and CD44þ/ALDHhigh (from 0.06% to 0.38%). However, the same subpopulations are not increased in the LAPC-9 model upon castration, while only the CD44-/ALDHhigh subset is enriched (from 3.5% to 7.1%). Organoids derived from bulk BM-18 and LAPC-9 tumors are reestablishing tumor formation upon intraosseous inoculation.
INTRODUCTION AND OBJECTIVES: Tumor heterogeneity can be traced back to a small subset of cancer stem cells (CSCs), which can be derived from a single stem cell and show chemo-resistance. Recent studies showed that CSCs are sensitive to the drug which targets mitochondrial phosphorylation. However, little is known about how cancer cells undergo sphere formation and how the drugs inhibit CSC proliferation.
METHODS: We cultured prostate cancer cell line (PC-3, LNCap, Du-145) under the non-adherent condition using sphereforming assay. Notably, Cells were plated in serum-free medium DMEM/F12 containing B27 without Vitamine A, 20 ng/ml EGF and 0.4% PenStrep in non-adherent conditions, in NunclonTM sphere dishes. All experiment was compared with the attached culture condition. All xenograft analysis was performed under the guidelines of the Kyushu University Animal Research Facility and were approved by the Kyushu University Institutional Care and Use Committee under Protocol #A29-052-0.
RESULTS: We show that under sphere-forming assay conditions, prostate cancer cells acquired CSC-like properties: promoted mitochondrial respiratory chain activity, expression of characteristic CSC markers and resistance to anticancer agents. Furthermore, those CSC-like properties could reversibly change depending on the culture conditions, suggesting some kinds of the properties have plasticity in tumor microenvironments. The sphere-forming cells (i.e. cancer stemlike cells) showed increased contact between mitochondria and mitochondrial associated-endoplasmic reticulum (ER) membranes (MAM). Mitochondrial targeting doxycycline-induced activating transcription factor 4 (ATF4) mediated expression of ER stress response and led to p53-upregulated modulator of apoptosis (PUMA)-dependent apoptosis only in the cancer stem-like cells. We also found that doxycycline effectively suppressed the sphere formation in vitro and blocked CD44v9-expressing tumor growth in vivo.
CONCLUSIONS: these data provide new molecular findings that monolayer cancer cells acquire CSC-like properties in a reversible manner. These findings provide important insights into CSC biology and a potential new treatment of targeting mitochondria dependency.
Source of Funding: none

MP81-18 INTRACAVERNOUS INJECTION OF BONE MARROW MESENCHYMAL STEM CELLS MODIFIED WITH PDE5-RNAI IMPROVES ERECTILE DYSFUNCTION IN AGED RATS
Hengjun Xiao*, Weixin Yan, Yubin Cui, Jun Chen, Liaoyuan Li, Guangzhou, China, People's Republic of INTRODUCTION AND OBJECTIVES: To determine the effect of intracavernous injection of bone marrow mesenchymal stem cells (BMSCs) genetically modified with PDE5-RNAi on erectile dysfunction (ED) in aged rats.
METHODS: BMSCs collected from Sprague-Dawley (SD) male rats of six weeks were transfected with lentivirus modified with PDE5-RNAi. Sixty male SD rats were equally divided into six groups: (i) A control group of normal rats (n¼10), (ii) A control group of Aged rats (n¼10), (iii) A negative control group of aged rats treated with PBS (n¼10), (iv) aged rats treated with BMSCs alone (n¼10), (v) aged rats treated with BMSCs modified with lentivirus-PDE5-RNAi (n¼10), (vi) aged rats treated with lentivirus-PDE5-RNAi (n¼10). ED was screened with apomorphine (100 mg/kg). Cell injections occurred directly into the corpora cavernosa (1Â106 cells). The ratio of intracavernosal pressure (ICP) to mean arterial pressure (MAP), expression of endothelial markers (such as CD31 and eNOS), smooth muscle markers (such as a-SMA and desmin), VEGF, b-FGF, Angiopoietin-1 and the relative area of smooth muscle to collagen using masson trichrome staining were assessed for each group.
RESULTS: Implanted BMSCs modified with PDE5-RNAi displayed a significantly raised ICP and ICP/MAP ratio (p < 0.05) compared with BMSCs and lentivirus-PDE5-RNAi alone in 14 days after intracavernous injection. Immunofluorescence staining displayed expression of CD31, eNOS and a-SMA was increased in BMSCs alone or BMSCs modified with PDE5-RNAi groups in aged rats after 2 weeks. Western blot analysis and quantitative analysis for western blot confirmed the significantly increased expression of CD31, eNOS and a-SMA (p < 0.05).VEGF, b-FGF, and Angiopoietin-1 were also significantly elevated 2 weeks following BMSCs modified with PDE5-RNAi injection (p < 0.05). After receiving intracaverous injection of BMSCs modified with PDE5-RNAi, smooth muscle cells/collagen ratio significantly increased confirmed by Masson's trichrome-staining. Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 THE JOURNAL OF UROLOGY â e1103 CONCLUSIONS: These results suggest that BMSCs modified with PDE5-RNAi treatment can enhance the recovery of erectile function in aged rats. METHODS: Thirty-six Lewis rats, aged 10-12 weeks, were divided into five groups: sham operation, bilateral cavernous nerve crush injury and bilateral internal pudendal bundle ligation without treatment (control), injury with MSC injection, injury with LESWT and MSC, injury with MSC and PDE5i, injury with LESWT, PDE5i, and MSC (n¼6 rats/group). The groups receiving MSCs were given a one-time intracavernosal injection of bone marrow-derived MSCs (2 million in 100ml of normal saline) at the time of injury. Forty-eight hours after injury groups were started on three times weekly LESWT (1000 pulses at 0.06 mJ/mm2 and 3Hz) or sildenafil was given by mouth mixed into daily drinking water at 5-20 mg/kg/day (water intake ad libitum) with a 1% sucrose additive, for four weeks. Following one week washout period (week 5), intracavernous pressure (ICP) was assessed at week 6 as a final outcome measure.
Source of Funding
RESULTS: Pelvic neurovascular injury resulted in a significant decrease in erectile function as measured by maximum ICP, average ICP and change in ICP (p¼0.003, 0.001, 0.007, respectively). MSC therapy alone resulted in partial recovery (average ICP, change in ICP compared to control group, p¼0.05, 0.037). When compared to the sham group, combination LESWT and MSC resulted in partial recovery (p¼0.08). The other combination therapies tested did not show significant (p>0.05) erectile recovery.
CONCLUSIONS: MSC alone and in combination with LESWT produced partial improvement of erectile function in a rat model of pelvic nerve injury. . The fate of grafted cells, however, is poorly characterized, and it is unknown if labeling technology impacts cellular function. Thus, alongside human placental stem cells (hPSC) we aim to use a novel dual-labeling technique featuring a red fluorescent protein variant mKATE and a new codon-optimized luciferase from Renilla Reniformis (mKATE-renLUC) using a lentivirus vector. We aim to determine the effect of labeling on in vitro function in preparation for future bioluminescence-tracking following intracavernosal administration.
METHODS: To optimize the transfection protocol, different hPSC concentrations, vectors (mKATE-renLUC, GFP-FLUC), and lentivirus titers were tested. Cell viability, proliferation, migration, and paracrine effects of hPSC expressing mKATE-renLUC were examined, and compared to non-labeled cells. Paracrine effects of labeled cells were examined using an angiogenesis array. Cell survival and distribution of hPSC expressing mKATE-renLUC were monitored by IVIS imaging system in vitro.
RESULTS: Cell viability, morphology, migration, and cell proliferation of mKATE-renLUC labeled hPSC were similar to those of nonlabeled cells in vitro. Cell survival and migration of renLUC-labeled hPSC were efficiently monitored using IVIS imaging system. The angiogenesis array demonstrated similar expression of factors from both cell types.
CONCLUSIONS: This study demonstrates that dual-labeling technology using mKATE-renLUC provides a safe and effective cell tracking approach with brighter fluorophores and codon optimized luciferase. This development is promising for longer and more effective in vivo stem cell tracking after intracavernosal administration in models of ED.
